A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.
[en] Interruption of a continuous subcutaneous insulin infusion, most often due to technical problems occurring during the night, is a not uncommon event whose metabolic consequences have received relatively little attention until now. We have therefore investigated the changes in blood glucose, plasma non-esterified fatty acids, 3-hydroxybutyrate, glucagon and free insulin in eight C-peptide negative Type 1 diabetic patients whose pumps were deliberately stopped between 23.00 h and 05.00 h. A control test with the pump functioning normally was carried out in each patient and the studies were randomized. Considering the values at 23.00 h as reference, interruption of the insulin infusion resulted in (1) a rapid decrease in plasma free insulin significant after 1 h and reaching a nadir of 6 +/- 2 mU/l after 6 h; (2) a rise in blood glucose which was significant at hour 3 and reached 17.4 +/- 1.9 mmol/l at hour 6; (3) a moderate increase in plasma nonesterified fatty acids which remained in the range of 700-800 mumol/l; (4) an early and linear rise in plasma 3-hydroxybutyrate, significant after 1 h and averaging 1290 +/- 140 mumol/l after 6 h; (5) a late increase (hour 5) in plasma glucagon. The second aim of our study was to provide for the patient a precise scheme of insulin supplements administered via the pump and based on blood glucose monitoring (Dextrostix - Glucometer) and semi-quantitative evaluation of ketonuria (Acetest). Resetting the pump at its basal rate at 05.00 h and giving insulin supplements (2-8 U) at 06.45 h (with the usual breakfast dose) and again at 10.00 h have proved efficacious in restoring satisfactory metabolic control by noon the day after starting the experiment. These results form practical recommendations to patients undergoing this type of accident.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Krzentowski, G.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Castillo, M.
Luyckx, A. S.
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.
Pirart J. (1977) Diabète et complications dégénératives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973. Diabète Metab 3:97-107.
Pickup J.C., Keen H., Parsons J.A., Alberti K.G.M.M. (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1:204-207.
Pickup J.C., Keen H. (1979) Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics. Lancet 1:1255-1258.
Tamborlane W., Sherwin R.S., Genel M., Felig P. (1979) Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable insulin-infusion pump. Lancet 1:1258-1261.
Keller U., Schade D.S. (1981) Current status of portable insulin infusion devices. Diabetologia 21:425-426.
Pickup J.C., Viberti G.C., Bilous R.W., Keen H., Alberti K.G.M.M., Home P.D., Binder C. (1982) Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia 22:175-179.
Champion M.C., Shepherd G.A.A., Rodger N.W., Dupre J. (1980) Continuous subcutaneous infusion of insulin in the management of diabetes mellitus. Diabetes 29:206-212.
Dole V.P., Meinertz H. (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235:2595-2599.
Nakagawa S., Nakayama H., Sossaki T., Yoshimo K., Yu Y., Shimozaki K., Aoki S., Mashimo K. (1973) Simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22:590-600.
Sulon J., Demey-Ponsart E., Bauduin P., Sodoyez J.C. (1978) Radioimmunoassay of corticosterone, cortisol and cortisone: their application to human cord and maternal plasma. J Steroid Biochem 9:671-676.
Heding L.G. (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548.
Kemmler W., Gerbitz K.D., Hauner H., Piwernetz K., Hepp K.D., Renner R. (1980) The insulin levels necessary for good metabolic control with intravenous insulin therapy. New approaches to insulin therapy , K., Irsigler, K.N., Kunz, D.R., Owens, H., Regal, MTP Press, Lancaster; 171-179.
Kraegen E.W. (1980) The necessity and feasibility of normalizing plasma insulin levels in diabetics using insulin delivery systems. New approaches to insulin therapy , K., Irsigler, K.N., Kunz, D.R., Owens, H., Regal, MTP Press, Lancaster; 249-256.
Gerich J.E., Lorenzi M., Bier D.M., Schneider V., Tsalikian E., Karam J.H., Forsham P.H. (1975) Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292:985-989.
McGarry J.D., Foster D.W. (1980) Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem 49:395-420.
Keen H., Pickup J.C., Viberti G.C., Bilous R., Willia G. (1981) Aspects of continuous subcutaneous insulin infusion in diabetes. Diabetes Care 4:54-57.
Fishman V., Fishman M. (1982) Practical problems with insulin pumps. New Engl J Med 306:1369.